50% off Premium Yearly
Agilent TechnologiesABUY ON WEAKNESSDec 18, 2024Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
Is up 55% from its April lows. They just reported a strong quarter with 7% organic growth. The business is turning around, helped by re-shoring in life sciences, plus the rise of some medicine that require more hardware to produce. The FDA is less disruptive as expected. The life sciences sector looks attractive.
It just affirmed its forecast of 5-7% annual revenue growth and steady operating margin expansion. Trades at only 22x 2025 PE.